Last $3.95 USD
Change Today 0.00 / 0.00%
Volume 0.0
ZLIXF On Other Exchanges
Symbol
Exchange
Continuous
OTC US
Frankfurt
OTC US
As of 4:30 PM 06/25/14 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZLIXF) Key Developments

Zeltia Announces Earnings Results for the Second Quarter and First Half Ended June 30, 2014

Zeltia announced earnings results for the second quarter and first half ended June 30, 2014. For the quarter, the company reported that loss attributable to equity-holders of the parent was €147,000, compared to a loss attributable to equity-holders of the parent of €1.41 million for the same quarter ended June 30, 2013. Total revenue was €44.92 million, compared to €41.03 million for the same quarter ended June 30, 2013. For the first half, the company reported net sales amounted to €78.2 million up 10% with respect to the same period last year. EBITDA amounted to €22.1 million in first half of 2014, a 12% increase with respect to the same period last year. The oncology area was the main contributor to this performance, accounting for €24 million against €22.5 million in first half of 2013. EBITDA increased notably despite the increase in R&D spending +9.8%, attributable mainly to the pivotal Phase III trial with Aplidin in multiple myeloma. Income attributable to equity-holders of the parent was €16.75 million, compared to €14.40 million for the same period ended June 30, 2013. Total revenue was €98.05 million, compared to €91.19 million for the same period ended June 30, 2013.

Zeltia SA to Report Q2, 2014 Results on Jul 29, 2014

Zeltia SA announced that they will report Q2, 2014 results on Jul 29, 2014

Zeltia S.A. Reports Earnings Results for the First Quarter Ended March 31, 2014

Zeltia S.A. reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported a profit attributable to owners of the parent of EUR 16.90 million compared to EUR 15.82 million for the same quarter ended March 31, 2013. Net revenues were EUR 34.21 million, compared to EUR 30.81 million for the same quarter ended March 31, 2013. Net operating profit was EUR 18.08 million compared to EUR 16.46 million for the same quarter ended March 31, 2013.

Zeltia SA Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:00 PM

Zeltia SA Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: José Luis Fernández Puentes, Director.

Zeltia SA Presents at Bank of America Merrill Lynch Health Care Conference, May-13-2014

Zeltia SA Presents at Bank of America Merrill Lynch Health Care Conference, May-13-2014 . Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLIXF:US $3.95 USD 0.00

ZLIXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLIXF.
View Industry Companies
 

Industry Analysis

ZLIXF

Industry Average

Valuation ZLIXF Industry Range
Price/Earnings 41.2x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 40.8x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.